Tariq Parvez

King Fahad Hospital Hofuf, Hofūf, Eastern Province, Saudi Arabia

Are you Tariq Parvez?

Claim your profile

Publications (17)6.67 Total impact

  • Tariq Parvez
    [Show abstract] [Hide abstract]
    ABSTRACT: The standard treatment for glioblastoma multiforme is surgery, radiation, and chemotherapy. Yet this aggressive therapy has only a modest effect on survival with most patients surviving less than 1 year after diagnosis. This poor prognosis has lead scientists to seek alternative molecular approaches for the treatment of glioblastoma multiforme. Among these, gene therapy, vaccine therapy, and immunotherapy are all approaches that are currently being investigated. While these molecular approaches may not herald an immediate change in the prognosis of these aggressive tumors, combining them with existing approaches may bring some progress in the standard of care. This paper reviews current treatments and several newer therapies in preclinical and early clinical studies.
    Technology in cancer research & treatment 07/2008; 7(3):241-8. DOI:10.1177/153303460800700310 · 1.73 Impact Factor
  • Tariq Parvez · Babar Parvez · Talal Moteab Alharbi
    [Show abstract] [Hide abstract]
    ABSTRACT: Gallbladder cancer is a relatively rare form of malignancy. As yet, the progress in its management is very slow, which leads to high mortality and very low survival. There is a dire need to help this class of patients by bringing in resources to find ways to reduce its dismal prognosis. At present, the best chances for this disease are early radical surgery. But in patients with invasion of adjacent organs, extended surgery, excising the invaded tissue, may be justified. In patients with distant lymph-node metastasis, even without adjacent organ invasion, radical surgery may not achieve a good outcome.1 Here, combination chemotherapy or chemo-radiotherapy may have some benefits.
    Journal of the College of Physicians and Surgeons--Pakistan: JCPSP 04/2007; 17(3):175-9. · 0.35 Impact Factor
  • Tariq Parvez · Talal Moteab Alharbi · Fan Dong Mein
    [Show abstract] [Hide abstract]
    ABSTRACT: To assess the effect of group psychotherapy in the management of the side effects of chemotherapy treatment in advanced breast and lung cancer. A randomized control study. This study was conducted in the department of Oncology, King Fahad Hospital, Madina Munawra, KSA, from January 2002 to June 2005. One hundred patients treated with chemotherapy for advanced stage (IIIB and IV) breast and lung cancer were selected with ECOG performance status of 0 or 1. All patients received anti-emetic medications half an hour before chemotherapy. All those patients in this category who completed fist line chemotherapy with 6 cycles were included. Fifty were subjected to group discussions with other patients, family members and medical staff. This was labeled group A. The other 50 were not included in group discussion and were labeled group B. Both the group received similar standard chemotherapy and pre-medication for vomiting as per their disease and chemotherapy schedule. Breast and lung cancer patients were 29 and 21 in each arm respectively. At the end of the discharge, grade 2 and above of vomiting, according to common terminology criteria for adverse events (CTCAE) was counted for all patients in both the arms A and B, over full length of treatment for 6 cycles, and then were compared statistically. Mean with standard deviation for adverse event (vomiting) in group A and B was 6.2 + 2.6 and 13.4 + 3.8 respectively per cycle of treatment. It was observed that group psychotherapy had statistically significant effect (p-value < 0.05) on the management of vomiting. Group psychotherapy can be used to reduce the incidence of vomiting in advanced breast and lung cancer patients treated with chemotherapy.
    Journal of the College of Physicians and Surgeons--Pakistan: JCPSP 03/2007; 17(2):89-93. · 0.35 Impact Factor
  • Tariq Parvez · Amal Behani · Akbar Ali
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the clinico-pathological status of Primary Gastric Lymphoma (PGL) at presentation in King Fahad Hospital, Madina Munawra, Kingdom of Saudi Arabia (KSA). A case series. PLACE AND DURATION OF SUDY: Oncology Department of King Fahad Hospital, Madina Munawra, KSA, from 1990 to 1998. Case records of 22 patients with a histologically-confirmed diagnosis of PGL were analyzed. Tumors were staged according to the Ann Arbor Classification and divided according to the Rappaport working formulation. According to the treatment modality, different groups were established. Any other histopathological type was excluded from the study. Data were analyzed by frequency calculations. Survival was calculated from the date of surgery. All cases were Non-Hodgkin Lymphoma (NHL). The peak age was in the sixth decades with a slight male preponderance. Most common presenting symptoms were epigastric or upper abdominal pain with or without mass. There were 10 (45%) patients with stage II, and 6 (27%) patients each with stage III and IV diseases. Diffuse large cell lymphoma was found in 12 (55%), poorly differentiated lymphoma in 3 (14%) and diffuse mixed in 7 (32%). Helicobacter pylori infection was found in 2 (9%). Sixteen (73%) patients underwent chemotherapy with some surgical resection, in 5 (23%) surgical procedure was palliative bypass and 11 (50%) had partial gastrectomy. Three (14%) had only chemotherapy after endoscopic biopsy. Two (9%) patients needed urgent surgical intervention. One (5%) patient had total gastrectomy followed by radiotherapy. Eleven (50%) had more than 3 years survival. PGL is usually of NHL type, presenting in the sixth decade, and can be successfully treated with both surgery and chemotherapy when patients presented at stage II. Chemotherapy after sub-total gastrectomy or biopsy was the best treatment option.
    Journal of the College of Physicians and Surgeons--Pakistan: JCPSP 02/2007; 17(1):36-40. · 0.35 Impact Factor
  • Tariq Parvez · Muhammad Imtiaz Ibraheim
    [Show abstract] [Hide abstract]
    ABSTRACT: A case of metastatic carcinoma of unknown primary is reported that had widely disseminated disease from the very outset. Every effort was made to find out the primary by integrating all results and specially tumor markers. It was assumed that lung was the most possible site for primary. Tumor markers did not show their diagnostic value even in combined panel, they only showed their prognostic value.
    Journal of the College of Physicians and Surgeons--Pakistan: JCPSP 03/2006; 16(2):154-6. · 0.35 Impact Factor
  • Tariq Parvez
    [Show abstract] [Hide abstract]
    ABSTRACT: Surgery, chemotherapy, and radiation therapy are standard modalities for cancer treatment. Biological therapy (immunotherapy, biotherapy, or biological response modifier therapy) is a comparatively novel addition to this armamentarium. Biological therapies use the body's immune system, either directly or indirectly, to fight cancer or to lessen the side effects that may be caused by some cancer treatments. Biological therapeutic agents include interferons, interleukins, colony-stimulating factors, monoclonal antibodies, vaccines, gene therapy, and nonspecific immunomodulating agents. A promising form of cancer treatment is immunotherapy. Immunotherapy for cancer is essentially the stimulation of the immune system through a variety of reagents such as vaccines, infusion of T-cells, or cytokines. These reagents act through one of several mechanisms including stimulating the anti-tumor response, decreasing suppressor mechanisms, altering tumor cells to increase their immunogenicity and making them more susceptible to immunologic defenses, and improving tolerance to cytotoxic agents or radiotherapy. This review describes some novel approaches in the immunotherapy in cancer.
    Journal of the College of Physicians and Surgeons--Pakistan: JCPSP 12/2005; 15(11):738-45. · 0.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This case report describes the occurrence of carcinoma in gastric stump in a man who underwent partial gastrectomy with anastomosis 20 years back for duodenal ulcer. Surgical resection and anastomosis was followed by adjuvant chemotherapy.
    Journal of the College of Physicians and Surgeons--Pakistan: JCPSP 09/2005; 15(8):502-4. · 0.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The growth factors (GFs) act at different stages of stem cell proliferation. Among them the most important ones found of clinical use are erythropoietin (EPO), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and thrombopoietin (TPO). Their concomitant use makes treatment with chemotherapy or radiotherapy easier and cost-effective, with fewer side effects and better quality of life in highly selected patients.
    Journal of the College of Physicians and Surgeons--Pakistan: JCPSP 07/2005; 15(6):375-7. · 0.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Metastatic disease is present at diagnosis in 30% of the patients with colorectal cancer (CRC), and approximately half of early-stage patients with CRC will eventually present with metastatic disease. Until recently, few chemotherapy options were available to treat metastatic colorectal carcinoma (MCRC). Fluorouracil (5-FU) with leucovorin (LV) modulation has a marginal but positive effect on survival in those patients. The recent incorporation of irinotecan (CPT-11) and oxaliplatin for the management of advanced CRC has generated further improvement in survival. The development of oral fluoropyrimidines, mimicking continuous infusion 5-FU, is convenient to use. Recently completed or ongoing clinical trials to study novel targeting agents have initiated a new era of drug development. Anti-angiogenesis drugs, tyrosine kinase inhibitors, and epidermal growth factor blockers are among the new generation of agents.
    Journal of the College of Physicians and Surgeons--Pakistan: JCPSP 11/2004; 14(10):638-42. DOI:10.2004/JCPSP.638642 · 0.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Liver cancer remains one of the most common causes of cancer death globally, and its cure rate has not improved for the past 20 years. Hepatocellular carcinoma develops in patients with cirrhosis of any etiology. Patients with cirrhosis are thus usually included in screening program aiming to achieve early detection and effective treatment for HCC. Only those patients diagnosed with HCC who would benefit with the available treatment, should undergo the screening procedure. This is based on ultrasonography and alpha-fetoprotein every 3-6 months based on the prevalence and economic status of the community being tested.
    Journal of the College of Physicians and Surgeons--Pakistan: JCPSP 10/2004; 14(9):570-5. · 0.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine the knowledge of doctors, nurses, patients and public about the causes of gastrointestinal cancers and dissemination of this knowledge. A cross-sectional analytical study. This study was carried out in the Department of Oncology, King Fahad Hospital, Al-Madinah Al-Munawara, Kingdom of Saudi Arabia and was completed in four months from February 2003 to June 2003. About 200 doctors, nurses and patients suffering from GIT cancer and general public were selected. Each subject was asked to fill up a proforma designed to assess his knowledge about the risk factors for GIT malignancies. A majority of doctors and nurses had good knowledge about the causes of GIT malignancies. The knowledge of patients and general public was low. Out of all four groups, it was poorest in the patient's group. The difference in the knowledge of medicos and patients/public reflects that medicos should convey this knowledge to the patients in particular and general public in general, which is their responsibility besides medical treatment.
    Journal of the College of Physicians and Surgeons--Pakistan: JCPSP 03/2004; 14(2):98-101. · 0.35 Impact Factor
  • Journal of the College of Physicians and Surgeons--Pakistan: JCPSP 02/2004; 14(1):57-60. · 0.35 Impact Factor
  • Tariq Parvez
    [Show abstract] [Hide abstract]
    ABSTRACT: Invasive fungal infections are important causes of morbidity and mortality in cancer patients with prolonged neutropenia following chemotherapy. Recent trends indicate a change toward infections by Aspergillus species, non-albicans species of Candida, and previously uncommon fungal pathogens. These have decreased susceptibility to current antifungal agents. In the last decade there has been much effort to find solution for these changing trends. This article reviews current approaches to prevention and treatment of opportunistic fungal infections in postchemotherapy neutropenic patients and discusses future antifungal approaches and supportive methods.
    Journal of the College of Physicians and Surgeons--Pakistan: JCPSP 12/2003; 13(11):669-73. · 0.35 Impact Factor
  • Tariq Parvez · Hamza Al-sisi · Imtiaz Ibraheim
    [Show abstract] [Hide abstract]
    ABSTRACT: Treatment of hormone-resistance cancer prostate (HRCP) is undergoing evolution. Chemotherapy is now increasingly being utilized. The steps involved in the hormone management and the role for chemotherapy in the current time are being discussed. Hormonal management is carried out at different stages of hormonal sensitivity by sequential hormonal use. Once hormonal resistance is established, the combination of mitoxantrone and prednisone become a standard chemotherapeutic approach. New agents, such as docetaxel, are being tested in phase-III trials against mitoxantrone plus prednisone. HRCP is now regarded as a chemotherapy-sensitive tumor. The goals of chemotherapy in HRCP are to decrease PSA level and improve quality of life. New agents and combinations are needed to improve survival to meet this end.
    Journal of the College of Physicians and Surgeons--Pakistan: JCPSP 11/2003; 13(10):606-10. DOI:10.2003/JCPSP.606610 · 0.35 Impact Factor
  • Abbas Ali Gumgumji · Talal Dawood · Tariq Parvez
    [Show abstract] [Hide abstract]
    ABSTRACT: Cyclooxygenase-2 (COX-2) is over expressed in a variety of premalignant and malignant conditions. It may contribute to carcinogenesis by modulating xenobiotic metabolism, apoptosis, immune surveillance, and angiogenesis. Selective COX-2 inhibitors suppress the formation of tumors in experimental models. Selective COX-2 inhibitors also suppress the growth and metastases of established tumors and enhance the anticancer activity of both radiotherapy and chemotherapy in experimental animals. This review aims at discussing evidence that inhibition of COX-2 represents a promising strategy to treat, prevent or possibly prevent human malignancies. Importantly, selective COX-2 inhibitors do not inhibit platelet function and cause fewer gastrointestinal side effects (peptic ulcer disease) than traditional nonsteroidal anti-inflammatory drugs (NSAIDS). More clinical trials are warranted to define the role of selective COX-2 inhibitors in the prevention and treatment of cancer along with their assessment of toxicity.
    Journal of the College of Physicians and Surgeons--Pakistan: JCPSP 07/2003; 13(6):361-5. · 0.35 Impact Factor
  • Tariq Parvez · Tariq Pervez
    [Show abstract] [Hide abstract]
    ABSTRACT: Ovarian cancer is very important malignancy of woman as far as its incidence and mortality is concerned. Although majority presents at late stage but still there is a reasonable response to currently available chemotherapy drugs and their use in multimodality setting. Besides good response to chemotherapy drugs, majority have recurrence. So there is a need for new drugs, new trends and their combinations. All these issues will be discussed in this review article.
    Journal of Ayub Medical College, Abbottabad: JAMC 01/2003; 15(2):65-8.

Publication Stats

37 Citations
6.67 Total Impact Points

Top co-authors View all


  • 2007
    • King Fahad Hospital Hofuf
      Hofūf, Eastern Province, Saudi Arabia
  • 2003–2006
    • King Fahad Hospital Medina La Munawarah Kingdom Of Saudi Arabia
      Al Madīnah al Munawwarah, Al Madīnah, Saudi Arabia
  • 2004
    • Vivantes Klinikum im Friedrichshain
      Berlín, Berlin, Germany